Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance
Dr Marianne Ratcliffe speaks with ecancertv at AACR 2016 about her work in establishing the comparative efficacy of three commercially available PDL-1 assays. With pembrolizumab gaining increasing traction as a therapy across an array of cancer types, many different assays are available from multiple manufacturers but with little data available on their interchangability. Dr Ratcliffe reports a high degree of concordance between three assays, and highlights the ongoing debate of using PDL-1 positive or negative results to influence patient medication as an area requiring further consideration with hopes to reach a broad agreement of test suitability.
